Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Pan-Cancer Integrative Analysis of Whole-Genome De novo Somatic Point Mutations Reveals 17 Cancer Types

Version 1 : Received: 11 November 2021 / Approved: 15 November 2021 / Online: 15 November 2021 (13:51:33 CET)

How to cite: Kazemi, A.; Ghareyazi, A.; Hamidieh, K.; Dashti, H.; Tahaei, M.; Rabiee, H.; Alinejad Rokny, H.; Dehzangi, A. Pan-Cancer Integrative Analysis of Whole-Genome De novo Somatic Point Mutations Reveals 17 Cancer Types. Preprints 2021, 2021110266 (doi: 10.20944/preprints202111.0266.v1). Kazemi, A.; Ghareyazi, A.; Hamidieh, K.; Dashti, H.; Tahaei, M.; Rabiee, H.; Alinejad Rokny, H.; Dehzangi, A. Pan-Cancer Integrative Analysis of Whole-Genome De novo Somatic Point Mutations Reveals 17 Cancer Types. Preprints 2021, 2021110266 (doi: 10.20944/preprints202111.0266.v1).

Abstract

The advent of high throughput sequencing has enabled researchers to systematically evaluate the genetic variations in cancer, resulting in identifying many cancer-associated genes. Although cancers in the same tissue are widely categorized in the same group, they demonstrate many differences concerning their mutational profiles. Hence there is no “silver bullet” for the treatment of a cancer type. This reveals the importance of developing a pipeline to identify cancer-associated genes accurately and re-classify patients with similar mutational profiles. Classification of cancer patients with similar mutational profiles may help discover subtypes of cancer patients who might benefit from specific treatment types. In this study, we propose a new machine learning pipeline to identify protein-coding genes mutated in a significant portion of samples to identify cancer subtypes. We applied our pipeline to 12270 samples collected from the International Cancer Genome Consortium (ICGC), covering 19 cancer types. Here we identified 17 different cancer subtypes. Comprehensive phenotypic and genotypic analysis indicates distinguishable properties, including unique cancer-related signaling pathways, in which, for most of them, targeted treatment options are currently available. This new subtyping approach offers a novel opportunity for cancer drug development based on the mutational profile of patients. We also comprehensive study the causes of mutations among samples in each subtype by mining the mutational signatures, which provides important insight into their active molecular mechanisms. Some of the pathways we identified in most subtypes, including the cell cycle and the Axon guidance pathways, are frequently observed in cancer disease. Interestingly, we also identified several mutated genes and different rates of mutation in multiple cancer subtypes. In addition, our study on “gene-motif” suggests the importance of considering both the context of the mutations and mutational processes in identifying cancer-associated genes. The source codes for our proposed clustering pipeline and analysis are publicly available at: https://github.com/bcb-sut/Pan-Cancer.

Keywords

Pan-Cancer; somatic point mutations; cancer subtyping; biomarker discovery; driver genes; per-sonalized medicine; health data analytics

Subject

ENGINEERING, Biomedical & Chemical Engineering

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.